What is B. Riley’s Forecast for CRBP Q1 Earnings?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) – Stock analysts at B. Riley issued their Q1 2025 earnings per share (EPS) estimates for Corbus Pharmaceuticals in a report released on Thursday, March 13th. B. Riley analyst K. Patel expects that the biopharmaceutical company will earn ($0.92) per share for the quarter. The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($4.23) per share. B. Riley also issued estimates for Corbus Pharmaceuticals’ Q2 2025 earnings at ($0.92) EPS and Q3 2025 earnings at ($0.92) EPS.

Corbus Pharmaceuticals (NASDAQ:CRBP) last released its earnings results on Tuesday, March 11th. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, beating the consensus estimate of ($1.02) by $0.24.

A number of other equities research analysts have also commented on the company. Jefferies Financial Group dropped their price target on Corbus Pharmaceuticals from $70.00 to $53.00 and set a “buy” rating on the stock in a research report on Tuesday. William Blair initiated coverage on Corbus Pharmaceuticals in a research report on Friday, February 28th. They set an “outperform” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target (down previously from $75.00) on shares of Corbus Pharmaceuticals in a research report on Wednesday. Piper Sandler initiated coverage on Corbus Pharmaceuticals in a research report on Monday, December 2nd. They set an “overweight” rating and a $35.00 price target on the stock. Finally, Wedbush reaffirmed an “outperform” rating and set a $51.00 price target on shares of Corbus Pharmaceuticals in a research report on Wednesday. One analyst has rated the stock with a sell rating, nine have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $59.13.

Corbus Pharmaceuticals Trading Up 5.8 %

NASDAQ:CRBP opened at $6.79 on Friday. Corbus Pharmaceuticals has a 1-year low of $6.38 and a 1-year high of $61.90. The business’s 50-day moving average price is $9.44 and its two-hundred day moving average price is $18.99. The firm has a market capitalization of $82.70 million, a price-to-earnings ratio of -1.45 and a beta of 2.63.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Charles Schwab Investment Management Inc. grew its holdings in shares of Corbus Pharmaceuticals by 224.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 93,643 shares of the biopharmaceutical company’s stock worth $1,932,000 after buying an additional 64,800 shares in the last quarter. State Street Corp grew its holdings in shares of Corbus Pharmaceuticals by 34.6% during the third quarter. State Street Corp now owns 595,576 shares of the biopharmaceutical company’s stock worth $12,287,000 after buying an additional 153,243 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Corbus Pharmaceuticals by 27.0% during the third quarter. JPMorgan Chase & Co. now owns 5,507 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 1,172 shares in the last quarter. Geode Capital Management LLC grew its stake in Corbus Pharmaceuticals by 8.1% in the third quarter. Geode Capital Management LLC now owns 249,759 shares of the biopharmaceutical company’s stock valued at $5,154,000 after purchasing an additional 18,702 shares in the last quarter. Finally, HighVista Strategies LLC grew its stake in Corbus Pharmaceuticals by 94.1% in the third quarter. HighVista Strategies LLC now owns 75,292 shares of the biopharmaceutical company’s stock valued at $1,553,000 after purchasing an additional 36,499 shares in the last quarter. 64.64% of the stock is currently owned by institutional investors.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.